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The aim of a clinical classification of pulmonary hypertension (PH) is to group together different manifestations
of disease sharing similarities in pathophysiologic mechanisms, clinical presentation, and therapeutic ap-
proaches. In 2003, during the 3rd World Symposium on Pulmonary Hypertension, the clinical classification of PH
initially adopted in 1998 during the 2nd World Symposium was slightly modified. During the 4th World Sympo-
sium held in 2008, it was decided to maintain the general architecture and philosophy of the previous clinical
classifications. The modifications adopted during this meeting principally concern Group 1, pulmonary arterial
hypertension (PAH). This subgroup includes patients with PAH with a family history or patients with idiopathic
PAH with germline mutations (e.g., bone morphogenetic protein receptor-2, activin receptor-like kinase type 1,
and endoglin). In the new classification, schistosomiasis and chronic hemolytic anemia appear as separate enti-
ties in the subgroup of PAH associated with identified diseases. Finally, it was decided to place pulmonary veno-
occlusive disease and pulmonary capillary hemangiomatosis in a separate group, distinct from but very close to
Group 1 (now called Group 1=). Thus, Group 1 of PAH is now more homogeneous. (J Am Coll Cardiol 2009;54:
S43–54) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.012P
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the classification of pulmonary hypertension (PH) has gone
hrough a series of changes since the first classification was
roposed in 1973 at an international conference on primary
H (PPH) endorsed by the World Health Organization
1,2). The initial classification designated only 2 categories,
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bsence of identifiable causes or risk factors. Twenty-five
ears later, the 2nd World Symposium on Pulmonary
rterial Hypertension (PAH) was held in Evian, France.
he “Evian classification” attempted to create categories of
H that shared pathologic and clinical features as well as
imilar therapeutic options (3). This was a much broader,
ore encompassing classification, with 5 major categories; it
llowed investigators to conduct clinical trials in a well-
efined group of patients with a shared underlying patho-
enesis. This has led to multiple clinical trials and the
pproval of 8 different medications worldwide for the
reatment of PAH.
The 3rd World Symposium on PAH was held in Venice,
taly, 5 years after the Evian conference. At this conference,
he impact and usefulness of the “Evian classification” was
eviewed, and modest changes were made. The most nota-
le change was to abandon the term PPH in favor of
diopathic pulmonary arterial hypertension (IPAH); familial
AH if there is a family history of PAH; or associated PAH
f another cause, such as connective tissue disease or human
mmunodeficiency virus (HIV), is present. Although the
erm PPH had become well ingrained in the literature after
resdale first used it in 1951 (4), it had become clear that
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sponse to therapy were similar in
several other conditions or dis-
eases. The term “secondary PH”
had been abandoned at the Evian
meeting because it was confusing
and did not help with diagnosis or
in directing treatment (5) (Table
1). The other prominent change
made at the Venice meeting was to
move pulmonary veno-occlusive
disease (PVOD) and pulmonary
capillary hemangiomatosis (PCH)
from separate categories into a sin-
gle subcategory of PAH. These 2
entities have many similarities
with each other, which will be
discussed later in this article, as
well as some similarities with
PAH. The 2008 4th World Sym-
posium on PH held in Dana
Point, California, provided the op-
portunity to slightly modify the
previous clinical classifications.
Dana Point Classification
During the 4th World Sympo-
sium on PH held in 2008 in
Dana Point, California, the con-
sensus of an international group
of experts was to maintain the
general philosophy and organiza-
tion of the Evian-Venice classi-
fications. However, in response
to a questionnaire regarding the
previous classification, a majority
of experts (63%) felt that modi-
cation of the Venice classification was required to accu-
ately reflect information published over the past 5 years, as
ell as to clarify some areas that were unclear. The current
ana Point classification is listed in Table 2, with major
hanges highlighted.
roup 1: PAH
ulmonary arterial hypertension has been the focus of the
lassification of PH since the first classification in 1973. The
omenclature of the subgroups and associated conditions
as evolved since that time, and additional modifications
ere made in the Dana Point classification.
.1./1.2. Idiopathic and heritable PAH. Pulmonary arte-
ial hypertension may occur in different clinical conditions
epending on associated diseases. Idiopathic PAH corre-
ponds to sporadic disease in which there is neither a family
Abbreviations
and Acronyms
BMPR2  bone
morphogenetic protein
receptor type 2
CHD  congenital heart
disease
CTEPH  chronic
thromboembolic pulmonary
hypertension
ESRD  end-stage renal
disease
HIV  human
immunodeficiency virus
IPAH  idiopathic
pulmonary arterial
hypertension
OR  odds ratio
PAH  pulmonary arterial
hypertension
PAP  pulmonary arterial
pressure
PCH  pulmonary capillary
hemangiomatosis
PH  pulmonary
hypertension
POPH  portopulmonary
hypertension
PPH  primary pulmonary
hypertension
PVOD  pulmonary veno-
occlusive disease
PVR  pulmonary vascular
resistance
SCD  sickle cell disease
TRV  tricuspid
regurgitation jet velocityistory of PAH nor an identified risk factor. When PAH lccurs in a familial context, germline mutations in the bone
orphogenetic protein receptor type 2 (BMPR2) gene, a
ember of the transforming growth factor  signaling
amily, can be detected in approximately 70% of cases (6,7).
ore rarely, mutations in activin receptor-like kinase type
, or endoglin, also members of the transforming growth
actor  signaling family, have been identified in patients
ith PAH, predominantly with coexistent hereditary hem-
rrhagic telangiectasia. Recently, it has been suggested that
atients with PAH associated with BMPR2 mutations may
epresent a subgroup of patients with more severe disease
ho are less likely to demonstrate vasoreactivity than those
ith IPAH without BMPR2 mutations (8–10).
Because BMPR2 mutations have also been detected in
1% to 40% of apparently idiopathic cases with no family
istory (11,12), the distinction between idiopathic and
amilial BMPR2 mutations is artificial. All patients with
MPR2 mutations have heritable disease, whether the
atient is the first identified case, possibly with a de novo
utation, or other family members were previously diag-
osed with PAH. In addition, in 30% or fewer families with
AH, no BMPR2 mutation has been identified. Thus, it
as decided to abandon the term “familial PAH” in the new
lassification and to replace it with the term “heritable
AH.” Heritable forms of PAH include IPAH with germ-
enice Clinical Classificationf Pulmonary Hypertension (2003)
Table 1 Venice Clinical Classificationof Pulmonary Hypertension (2003)
1. Pulmonary arterial hypertension (PAH)
1.1. Idiopathic (IPAH)
1.2. Familial (FPAH)
1.3. Associated with (APAH)
1.3.1. Collagen vascular disease
1.3.2. Congenital systemic-to-pulmonary shunts
1.3.3. Portal hypertension
1.3.4. HIV infection
1.3.5. Drugs and toxins
1.3.6. Other (thyroid disorders, glycogen storage disease, Gaucher disease,
hereditary hemorrhagic telangiectasia, hemoglobinopathies,
myeloproliferative disorders, splenectomy)
1.4. Associated with significant venous or capillary involvement
1.4.1. Pulmonary veno-occlusive disease (PVOD)
1.4.2. Pulmonary capillary hemangiomatosis (PCH)
1.5. Persistent pulmonary hypertension of the newborn
2. Pulmonary hypertension with left heart disease
2.1. Left-sided atrial or ventricular heart disease
2.2. Left-sided valvular heart disease
3. Pulmonary hypertension associated with lung diseases and/or hypoxemia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Sleep-disordered breathing
3.4. Alveolar hypoventilation disorders
3.5. Chronic exposure to high altitude
3.6. Developmental abnormalities
4. Pulmonary hypertension owing to chronic thrombotic and/or embolic disease
4.1. Thromboembolic obstruction of proximal pulmonary arteries
4.2. Thromboembolic obstruction of distal pulmonary arteries
4.3. Nonthrombotic pulmonary embolism (tumor, parasites, foreign material)
5. Miscellaneous
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary
vessels (adenopathy, tumor, fibrosing mediastinitis)ine mutations (mainly BMPR2 but also activin receptor-
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June 30, 2009:S43–54 Classification and Epidemiologyike kinase 1 or endoglin) and familial cases with or without
dentified germline mutations (13,14). The new category of
heritable PAH” does not mandate genetic testing in
atients with IPAH or in familial cases of PAH. Genetic
esting, when called for, should be performed as a part of a
omprehensive program that includes genetic counseling
nd discussion of the risks, benefits, and limitations of such
esting (15).
.3. Drug- and toxin-induced PAH. A number of risk
actors for the development of PAH have been identified
nd were included in the previous Evian and Venice
lassifications (3,5). Risk factors for PAH include “any
actor or condition that is suspected to play a predisposing
r facilitating role in the development of the disease. Risk
actors may include drugs and chemicals, diseases, or phe-
otype (age, gender).” Risk factors were categorized as
efinite, very likely, possible, or unlikely, based on the
strength of their association with PH and their probable
pdated Clinical Classification ofulmonary Hyperten ion (Dana Point, 2008)
Table 2 Updated Clinical Classification ofPulmonary Hypertension (Dana Point, 2008)
1. Pulmonary arterial hypertension (PAH)
1.1. Idiopathic PAH
1.2. Heritable
1.2.1. BMPR2
1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic
telangiectasia)
1.2.3. Unknown
1.3. Drug- and toxin-induced
1.4. Associated with
1.4.1. Connective tissue diseases
1.4.2. HIV infection
1.4.3. Portal hypertension
1.4.4. Congenital heart diseases
1.4.5. Schistosomiasis
1.4.6. Chronic hemolytic anemia
1.5 Persistent pulmonary hypertension of the newborn
1=. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary
hemangiomatosis (PCH)
2. Pulmonary hypertension owing to left heart disease
2.1. Systolic dysfunction
2.2. Diastolic dysfunction
2.3. Valvular disease
3. Pulmonary hypertension owing to lung diseases and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6. Chronic exposure to high altitude
3.7. Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1. Hematologic disorders: myeloproliferative disorders, splenectomy
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell
histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid
disorders
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure
on dialysis
ain modifications to the previous Venice classification are in bold.
ALK1 activin receptor-like kinase type 1; BMPR2 bone morphogenetic protein receptor type
; HIV  human immunodeficiency virus.ausal role.” In the current classification, the categorization Pf risk factors and the likelihood of developing PAH have
een modified. Updated risk factors and associated condi-
ions for PAH are presented in Table 3. A “definite”
ssociation is defined as an epidemic, such as occurred with
ppetite suppressants in the 1960s, or large, multicenter
pidemiologic studies demonstrating an association between
drug and PAH. A “likely” association is defined as a
ingle-center, case-control study demonstrating an associa-
ion or a multiple-case series. “Possible” is defined as drugs
ith similar mechanisms of action as those in the “definite”
r “likely” categories but which have not yet been studied
e.g., drugs used to treat attention-deficit disorder). Lastly,
n “unlikely” association is defined as one in which a drug
as been studied in epidemiologic studies and an association
ith PAH has not been demonstrated.
Aminorex, fenfluramine derivatives, and toxic rapeseed
il represent the only identified “definite” risk factors for
AH (3,5). A recent retrospective analysis of more than 100
ases of PAH associated with fenfluramine exposure showed
hat this category shares clinical, functional, hemodynamic,
nd genetic features with IPAH, suggesting that fenflura-
ine exposure represents a potential trigger for PAH
ithout influencing its clinical course (16).
The most recent surveillance study of PH, Surveillance of
ulmonary Hypertension in America (SOPHIA), enrolled
,335 subjects at tertiary PH centers in the U.S. between
998 and 2001 (17). This study confirmed the association of
enfluramine and dexfenfluramine intake with the develop-
ent of PAH. The average monthly number of IPAH cases
id not change during the study, which was, however,
onducted after fenfluramine and its derivates had been
ithdrawn from the U.S. market. A novel finding was that
t. John’s Wort (odds ratio [OR]: 3.6, vs. thromboembolic
H) and over-the-counter antiobesity agents containing
henylpropanolamine (OR: 5.2, vs. thromboembolic PH)
lso increased the risk of developing IPAH.
The SOPHIA study examined intake of a variety of
onselective monoamine reuptake inhibitors, selective sero-
onin reuptake inhibitors, antidepressants, and anxiolytics,
nd found no increased risk for developing PAH (17).
owever, a recent case-control study of selective serotonin
pdated Risk Factors forn Assoc ated Conditi ns of PAH
Table 3 Updated Risk Factors forand Associated Conditions of PAH
Definite Possible
Aminorex Cocaine
Fenfluramine Phenylpropanolamine
Dexfenfluramine St. John’s Wort
Toxic rapeseed oil Chemotherapeutic agents
SSRI
Likely Unlikely
Amphetamines Oral contraceptives
L-tryptophan Estrogen
Methamphetamines Cigarette smokingAH  pulmonary arterial hypertension; SSRI  selective serotonin reuptake inhibitor.
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Classification and Epidemiology June 30, 2009:S43–54euptake inhibitor use in pregnant women after 20 weeks of
estation showed an increased risk (OR: 6.1) in the off-
pring of developing persistent PH of the newborn, a form
f PAH (18). Based on this study, selective serotonin
euptake inhibitors may play a role in the development of
H, at least in association with pregnancy, and therefore
hey have been reclassified in the “possible” category.
Amphetamine use represents a “likely” risk factor for
AH, although they are rarely taken as a single agent and
re frequently used in combination with fenfluramine. A
ecent comprehensive retrospective study suggested a strong
elationship with the use of methamphetamine (inhaled,
moked, oral, or intravenous) and the occurrence of IPAH
19). Based primarily on the results of this study, metham-
hetamine use is now considered a “very likely” risk factor
or the development of PAH. Additional changes in drug-
nd toxin-induced PAH will be discussed later. With the
xception of hereditary hemorrhagic telangiectasia associ-
ted with PAH, the first 3 subcategories of Group 1,
diopathic, heritable, and drug- and toxin-induced PAH,
re all associated with the development of isolated pulmo-
ary arterial diseases.
.4.1. PAH associated with connective tissue diseases.
AH associated with connective tissue diseases represents
n important clinical subgroup. The prevalence of PAH has
een well established only for systemic sclerosis. Two recent
rospective studies using echocardiography as a screening
ethod and right heart catheterization for confirmation
ound a prevalence of PAH of between 7% and 12% (20,21).
everal long-term studies suggest that the outcome of
atients with PAH associated with systemic sclerosis is
arkedly worse than that of patients with IPAH, despite
he use of modern therapies.
Importantly, PAH does not represent the only cause of
H in systemic sclerosis. Pulmonary hypertension owing to
ung fibrosis is also frequent (22), and diastolic left heart
ysfunction is not uncommon (23). There is also primary
ardiac involvement in the disease process (24). These
bservations emphasize the importance of a complete eval-
ation when PH is suspected in patients with systemic
clerosis and the need for right heart catheterization to
onfirm the diagnosis of PH and to accurately classify its
tiology to determine appropriate treatment.
In systemic lupus erythematosis (25,26) and mixed con-
ective tissue disease (27,28), the prevalence of PAH
emains unknown but likely occurs less frequently than in
ystemic sclerosis. In the absence of fibrotic lung disease,
AH has been reported infrequently in other connective
issue diseases such as Sjögren syndrome (29), polymyositis
30), or rheumatoid arthritis (31).
.4.2. HIV infection. Pulmonary arterial hypertension is a
are but well-established complication of HIV infection
32,33). Epidemiologic data in the early 1990s, a time when
herapy with highly active antiretroviral therapy was not yet
vailable, indicated a prevalence of 0.5% (95% confidence
nterval: 0.10% to 0.50%) (34). The prevalence of HIV- pssociated PAH was evaluated more recently and showed a
table prevalence of 0.46% (95% confidence interval: 0.32%
o 0.64%) (35). Human immunodeficiency virus-associated
AH has clinical, hemodynamic, and histologic character-
stics similar to those seen in IPAH. The mechanism for the
evelopment of PH remains unclear. Because neither the
irus nor viral DNA has been found in pulmonary endo-
helial cells, an indirect action of virus through secondary
essengers such as cytokines, growth factors, endothelin, or
iral proteins is strongly suspected.
Uncontrolled studies suggest that patients with severe
IV-associated PAH could benefit from bosentan or long-
erm infusion of epoprostenol (36,37). Interestingly, in a
ubstantial number of cases, normalization of pulmonary
ascular hemodynamics can be obtained with therapy indi-
ated for PAH; this is very rarely seen in IPAH (38).
.4.3. Portopulmonary hypertension. The development
f PAH in association with elevated pressure in the portal
irculation is known as portopulmonary hypertension
POPH) (39,40). Portal hypertension, rather than the
resence of underlying liver disease, is the main determining
isk factor for the development of POPH. Prospective
emodynamic studies have shown that 2% to 6% of patients
ith portal hypertension have PH (41,42). Right heart
atheterization is absolutely mandatory for the definitive
iagnosis of POPH because several factors may increase
ulmonary arterial pressure (PAP) in the setting of ad-
anced liver disease (e.g., high flow associated with the
yperdynamic circulatory state and increased pulmonary
apillary wedge pressure owing to fluid overload and/or
iastolic dysfunction). Pulmonary vascular resistance (PVR)
s usually normal in these cases. Pathologic changes in the
mall arteries appear identical to those seen in IPAH. A
ecent multicenter case-control study identified 2 risk fac-
ors for the development of POPH: female sex and auto-
mmune hepatitis (43). Interestingly, hepatitis C infection
as associated with a decreased risk. A recent, large cohort
tudy of POPH showed that long-term prognosis was
elated to the presence and severity of cirrhosis and to
ardiac function (44).
.4.4. Congenital heart diseases. A significant proportion
f patients with congenital heart disease (CHD), in partic-
lar those with relevant systemic-to-pulmonary shunts, will
evelop PAH if left untreated. Persistent exposure of the
ulmonary vasculature to increased blood flow, as well as
ncreased pressure, may result in pulmonary obstructive
rteriopathy, which leads to increased PVR that will result
n shunt reversal. Eisenmenger syndrome is defined as
HD with an initial large systemic-to-pulmonary shunt
hat induces progressive pulmonary vascular disease and
AH, with resultant reversal of the shunt and central
yanosis (45,46). Eisenmenger syndrome represents the
ost advanced form of PAH associated with CHD. The
istopathologic and pathobiologic changes seen in patients
ith PAH associated with congenital systemic-to-
ulmonary shunts (e.g., endothelial dysfunction of the
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June 30, 2009:S43–54 Classification and Epidemiologyulmonary vasculature) are similar to those observed in
diopathic or other associated forms of PAH.
It has been reported that a large proportion of patients
ith CHD develop some degree of PAH (47–49). The
revalence of PAH associated with congenital systemic-to-
ulmonary shunts in Europe and North America has been
stimated to range between 1.6 and 12.5 cases per million
dults, with 25% to 50% of this population affected by
isenmenger syndrome (50). Following the Dana Point
eeting, it was decided to update the pathologic and
athophysiologic classification of CHD with systemic-to-
natomic-Pathophysiologic Classificationf Congenit l Systemic-to-Pulmonaryhunts Associated W th Pulmonary Arterialyperten on (Mo ified From Ve ce 2003)
Table 4
Anatomic-Pathophysiologic Classification
of Congenital Systemic-to-Pulmonary
Shunts Associated With Pulmonary Arterial
Hypertension (Modified From Venice 2003)
1. Type
1.1. Simple pre-tricuspid shunts
1.1.1. Atrial septal defect (ASD)
1.1.1.1. Ostium secundum
1.1.1.2. Sinus venosus
1.1.1.3. Ostium primum
1.1.2. Total or partial unobstructed anomalous pulmonary venous return
1.2. Simple post-tricuspid shunts
1.2.1. Ventricular septal defect (VSD)
1.2.2. Patent ductus arteriosus
1.3. Combined shunts (describe combination and define predominant defect)
1.4. Complex congenital heart disease
1.4.1. Complete atrioventricular septal defect
1.4.2. Truncus arteriosus
1.4.3. Single ventricle physiology with unobstructed pulmonary blood flow
1.4.4. Transposition of the great arteries with VSD (without pulmonary stenosis)
and/or patent ductus arteriosus
1.4.5. Other
2. Dimension (specify for each defect if 1 congenital heart defect)
2.1. Hemodynamic (specify Qp/Qs)*
2.1.1. Restrictive (pressure gradient across the defect)
2.1.2. Nonrestrictive
2.2. Anatomic
2.2.1. Small to moderate (ASD 2.0 cm and VSD 1.0 cm)
2.2.2. Large (ASD 2.0 cm and VSD 1.0 cm)
3. Direction of shunt
3.1 Predominantly systemic-to-pulmonary
3.2 Predominantly pulmonary-to-systemic
3.3 Bidirectional
4. Associated cardiac and extracardiac abnormalities
5. Repair status
5.1. Unoperated
5.2. Palliated (specify type of operation[s], age at surgery)
5.3. Repaired (specify type of operation[s], age at surgery)
Ratio of pulmonary (Qp) to systemic (Qs) blood flow.
linical Classification of Congenital Systemic-to-Pulmonary Shunts
Table 5 Clinical Classification of Congenital Systemic-to-Pulmo
A. Eisenmenger syndrome Includes all systemic-to-pulmona
a reversed (pulmonary-to-syst
are present
B. PAH associated with systemic-to-pulmonary
shunts
Includes moderate to large defe
and no cyanosis is present at
C. PAH with small defects Small defects (usually ventricula
by echocardiography); clinica
D. PAH after corrective cardiac surgery Congenital heart disease has be
or years after surgery in the aAH  pulmonary arterial hypertension; PVR  pulmonary vascular resistance.ulmonary shunts (Table 4) to provide a more detailed
escription of each condition. This anatomic and patho-
hysiologic classification may be too complex to be used in
linical practice; however, 4 quite distinct phenotypes can be
ecognized (Table 5).
.4.5. Schistosomiasis. Another important modification of
he new classification is the inclusion of PH associated with
chistosomiasis in Group 1.
In the previous classification, this form of PH was
ubcategorized in Group 4 as PH owing to chronic throm-
otic and/or embolic disease. Embolic obstruction of pul-
onary arteries by schistosoma eggs was thought to be the
rimary mechanism responsible for the development of PH
51). However, more recent publications indicate that PH
ssociated with schistosomiasis can have a similar clinical
resentation to IPAH (52), with similar histologic findings,
ncluding the development of plexiform lesions (53). The
echanism of PAH in patients with schistosomiasis is
robably multifactorial. It may include POPH, a frequent
omplication of this disease (54), and local vascular inflam-
ation as a result of impacted schistosoma eggs, whereas
echanical obstruction by schistosoma eggs seems to play a
inor role. PAH associated with schistosomiasis represents
frequent form of PAH, especially in countries in which the
nfection is endemic. It is estimated that more than 200
illion people are infected with any of the 3 species of
chistosoma and that 4% to 8% of patients will develop
epatosplenic disease. Data from a recent study based on
nvasive hemodynamics showed that the prevalence of PAH
n patients with hepatosplenic disease was 4.6%; also im-
ortant was the prevalence of post-capillary hypertension
3.0%), reinforcing the need for invasive hemodynamics for
he proper diagnosis of PAH in schistosomiasis (55).
.4.6. Chronic hemolytic anemia. The chronic hemolytic
nemias represent a new subcategory of PAH; these were
reviously categorized under “other” as conditions associ-
ted with the development of PAH. Since the Venice
lassification, there has been increasing evidence that PAH
s a complication of chronic hereditary and acquired hemo-
ytic anemias, including sickle cell disease (SCD) (56,57),
halassemia (58), hereditary spherocytosis (59), stomatocy-
osis (60), and microangiopathic hemolytic anemia (61).
Pulmonary hypertension has been described most fre-
uently in patients with SCD with histologic lesions similar
ciated to PAH
Shunts Associated to PAH
nts resulting from large defects and leading to a severe increase in PVR and
or bidirectional shunt; cyanosis, erythrocytosis, and multiple organ involvement
R is mildly to moderately increased, systemic-to-pulmonary shunt is still prevalent,
al defects 1 cm and atrial septal defects 2 cm of effective diameter assessed
e is very similar to idiopathic PAH
rected, but PAH is still present immediately after surgery or recurs several months
e of significant postoperative residual lesionsAsso
nary
ry shu
emic)
cts; PV
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Classification and Epidemiology June 30, 2009:S43–54o those found in IPAH, including plexiform lesions in 1
ase series (62). However, the prevalence of PAH in SCD
s not clearly established. The largest study of patients with
CD, which defined PH echocardiographically by the
resence of tricuspid regurgitation jet velocity (TRV) 2.5
/s, found that 32% of patients had PH (57). However,
sing a TRV 2.5 m/s on echocardiography to define PH
an lead to a substantial number of false positive cases of PH
ot confirmed by right heart catheterization (35,63). When
TRV 3.0 m/s was used, corresponding to an estimated
ystolic PAP of41 mm Hg, only 9% of the cohort met the
riteria for PH. Right heart catheterization was carried out
n only 18 of 63 patients with TRV 2.5 m/s. In this
ubpopulation, PH defined by a mean PAP 25 mm Hg
as confirmed in 17 patients; however, pulmonary wedge
ressure was elevated in some patients. A substantial pro-
ortion of patients with SCD have pulmonary venous
ypertension: 46% in 1 study of 26 patients with SCD and
H (64). In addition, some patients present with a hyperki-
etic state with moderate elevation in mean PAP and
ormal PVR. Thus, although it appears that some patients
ith SCD do develop PAH, the prevalence of PAH in
CD is undoubtedly much lower than 32%. Prospective
pidemiologic studies using echocardiographic screening
nd direct hemodynamic confirmation with right heart
atheterization in all patients with suspected PH are ongo-
ng and will evaluate the precise prevalence of PAH in
CD. The mechanism of PAH in SCD remains uncertain.
probable hypothesis is that chronic hemolysis results in
igh rates of nitric oxide consumption and produces a state
f resistance to nitric oxide bioactivity (65). Consequently,
mooth muscle guanosine monophosphate, a potent vaso-
ilator/antiproliferative mediator, is not activated (66).
roup 1=: PVOD and/or PCH
he conditions of PVOD and PCH are uncommon, but
hey are increasingly recognized as causes of PH (67). In the
vian classification, these 2 entities were placed in 2
ifferent groups, both distinct from PAH: PVOD was
ncluded in the pulmonary venous hypertension category,
nd PCH was included in the heterogeneous group of
isorders believed to directly affect the pulmonary vascula-
ure. Pathologic studies indicate, however, that PVOD and
CH are often quite similar in terms of changes in the
ulmonary parenchyma (i.e., pulmonary hemosiderosis, in-
erstitial edema, and lymphatic dilation) and the develop-
ent of pulmonary arterial intimal fibrosis and medial
ypertrophy. Similarities in pathologic features and clinical
resentation suggest that these disorders may overlap. Ac-
ordingly, in the Venice classification, PVOD and PCH
ere placed together as a subgroup of PAH.
PVOD and PCH were included in Group 1 for a numberf reasons. First, the histologic changes in the small pulmo- nary arteries (i.e., intimal fibrosis and medial hypertrophy)
re also found in PAH. Second, the clinical presentations of
VOD/PCH and PAH are often indistinguishable and
nrecognized antemortem (5). Third, PVOD/PCH and
AH share similar risk factors. These include the sclero-
erma spectrum of disease (68), HIV infection (69,70), and
he use of anorexigens. Fourth, in addition to the well-
escribed familial association with PAH, familial occur-
ence has been reported with both PVOD and PCH (67).
astly, mutations in BMPR2, the gene associated with
amilial PAH and IPAH, have been documented in patients
ith PVOD (71,72). These findings suggest that PVOD,
CH, and PAH may represent different components of a
ingle spectrum of disease.
The present decision to leave PVOD and PCH together
n the same subgroup is supported by a recent clinicopath-
logic study (73) analyzing 38 specimens (autopsies [n 
5], surgical biopsies [n  15], explants [n  7], and
neumonectomy [n  1]) from 35 patients diagnosed as
aving either PVOD (n  30) or PCH (n  5). PCH was
dentified in 24 (73%) patients diagnosed as having PVOD,
ither as perivenular foci or diffuse involvement of the
ulmonary parenchyma. In 5 patients diagnosed with
CH, 4 showed the venous and arterial changes charac-
eristic of PVOD. These findings suggest that PCH
ould be an angioproliferative process frequently associ-
ted with PVOD.
Recent evidence supports leaving PVOD and PCH
ogether; however, it is apparent that although they may
resent similarly to IPAH, there are a number of important
ifferences. These include the presence of crackles and
lubbing on examination, ground glass opacities, septal
hickening, mediastinal adenopathy on chest computed
omography (74–76), hemosiderin-laden macrophages on
ronchoalveolar lavage (77), and a lower carbon monoxide
iffusing capacity and PaO2 in patients with PVOD or
CH (71). In addition, the management, response to
edical therapy, and prognosis of PVOD/PCH are quite
ifferent than that of PAH. A recent study compared 24
atients with histologic evidence of PVOD with or without
CH and 24 randomly selected patients with idiopathic,
amilial, or anorexigen-associated PAH (71). Among the 16
atients with PVOD who received PAH-specific therapy, 7
43.8%) developed pulmonary edema. These patients were
reated mainly with continuous intravenous epoprostenol,
ut also with oral therapies, bosentan, and calcium channel
lockers. Clinical outcomes were worse in patients with
VOD than those with PAH.
PVOD/PCH remains a difficult disorder to categorize
ecause it shares characteristics with IPAH but also has a
umber of distinct differences. Given the current evidence,
t was decided that PVOD/PCH should be a distinct
ategory but not completely separated from PAH. There-
ore, in the current classification, PVOD/PCH is desig-
ated as 1=.
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eft heart disease probably represents the most frequent
ause of PH (78). Left-sided ventricular or valvular diseases
ay produce an increase in left atrial pressure, with passive
ackward transmission of the pressure leading to increased
AP. In this situation, PVR is normal or near normal (3.0
ood units) and there is no gradient between mean PAP
nd pulmonary wedge pressure (transpulmonary gradient
12 mm Hg). In the Venice classification, 2 broad subcat-
gories were recognized in this group based on the presence
r absence of valvular disease: PH owing to left atrial or
entricular disease and PH owing to left-sided valvular
isease (mitral and/or aortic). In the Venice classification,
his category was referred to as PH with left heart disease.
he new heading for this classification more appropriately
enotes cause and effect for this group of heterogeneous
isorders on the development of PH. In addition, with
ncreasing recognition of left-sided heart dysfunction with
reserved ejection fraction, the subcategories of Group 2
ave been modified and now include 3 distinct etiologies:
eft heart systolic dysfunction, left heart diastolic dysfunc-
ion, and left heart valvular disease.
Importantly, in some patients with left heart disease, the
levation of PAP is out of proportion to that expected from
he elevation of left arterial pressure (transpulmonary gra-
ient 12 mm Hg) and PVR is increased to 3.0 Wood
nits. In patients referred to cardiac transplant clinics, PH
ith PVR 3.0 Wood units is reported in 19% to 35% of
atients (78,79). Some patients with left heart valvular
isease or even left heart dysfunction can develop severe PH
f the same magnitude as that seen in PAH (80–82). The
levation of PAP and PVR is due to either the increase of
ulmonary artery vasomotor tone and/or pulmonary vascu-
ar remodeling (83,84). No studies using medications ap-
roved for PAH have been performed in this patient
opulation, and the efficacy and safety of PAH medications
emain unknown.
roup 3: PH Owing to
ung Diseases and/or Hypoxia
n this category, the predominant cause of PH is alveolar
ypoxia as a result of lung disease, impaired control of
reathing, or residence at high altitude. The prevalence of
H in all of these conditions remains largely unknown. In
he present classification, the structure of this group was for
he most part unchanged. The heading has been modified,
gain to denote cause and effect on the development of PH.
he primary modification in this group was to add a
ategory of lung disease characterized by a mixed obstructive
nd restrictive pattern. This new subgroup includes chronic
ronchiectasis, cystic fibrosis (85), and a newly identified
yndrome characterized by the combination of pulmonary
brosis, mainly of the lower zones of the lung, and emphy-
ema, mainly of the upper zones of the lung (86). In the fyndrome of combined pulmonary fibrosis and emphysema,
he prevalence of PH is almost 50% (86).
In patients with parenchymal lung disease, PH is gener-
lly modest (mean PAP 25 to 35 mm Hg) (87). However,
n some patients, PAP elevations can be more substantial
mean PAP 35 to 50 mm Hg) (88). In such patients,
articularly those with only moderate pulmonary mechani-
al impairment, this is considered “out-of-proportion” PH.
n a recent retrospective study of 998 patients with chronic
bstructive pulmonary disease who underwent right heart
atheterization, only 1% had severe pulmonary hypertension
mean PAP 40 mm Hg) (89). The authors described an
nusual pattern of cardiopulmonary abnormalities in the
atients with more severe PH, including mild to moderate
irway obstruction, severe hypoxemia, hypocapnia, and a
ery low diffusing capacity for carbon monoxide. As with
H out of proportion to left heart disease, large random-
zed, controlled studies of medications approved for PAH
re not available for PH out of proportion for parenchyma
ung disease.
roup 4: Chronic Thromboembolic PH
n the Venice classification, Group 4 was very heterogeneous
nd included obstruction of pulmonary arterial vessels by
hromboemboli, tumors, or foreign bodies. However, depend-
ng on the origin of the obstruction, the clinical presentation
nd radiologic findings are often different, and management is
nique to each etiology. Chronic thromboembolic pulmonary
ypertension (CTEPH) represents a frequent cause of PH.
he incidence of CTEPH is uncertain, but it occurs in up to
% of patients after an acute pulmonary embolism (90,91). In
ontrast, other obstructive etiologies are very rare. It was
ecided, therefore, to maintain only CTEPH in Group 4. In
he Venice classification, CTEPH was divided into 2 sub-
roups: proximal CTEPH, accessible to pulmonary thrombo-
ndarterectomy, and distal CTEPH, which is not accessible to
urgery. In practice, however, this distinction may be quite
nclear, and it may vary depending on individual centers.
urrently there is no consensus among experts about the
efinitions of proximal and distal CTEPH (92). Thus, it was
urther decided to maintain in Group 4 only a single category
f CTEPH and not to attempt to distinguish between proxi-
al and distal forms.
Importantly, it is strongly recommended that patients
ith suspected or confirmed CTEPH be referred to a center
ith expertise in the management of this disease to consider
he feasibility of performing pulmonary thromboendarter-
ctomy, currently the only curative treatment. The decision
epends on the location of the obstruction (central vs. more
istal pulmonary arteries), the correlation between hemo-
ynamic findings and the degree of mechanical obstruction
ssessed by angiography, comorbidities, the willingness of
he patient, and the experience of the surgeon (93,94).
atients who are not candidates for surgery may benefitrom PAH-specific medical therapy (95,96); however, the
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Classification and Epidemiology June 30, 2009:S43–54se of these medications in CTEPH requires further eval-
ation in randomized, controlled trials (97).
roup 5: PH With Unclear
r Multifactorial Etiologies
roup 5 consists of several forms of PH for which the
tiology is unclear or multifactorial.
.1. The first subgroup comprises several hematologic dis-
rders. PH has been reported in chronic myeloproliferative
isorders including polycythemia vera, essential thrombocy-
hemia, and chronic myeloid leukemia (98). Chronic myelo-
roliferative disorders can cause PH by various potential
echanisms. High cardiac output, auto or surgical asplenia,
irect obstruction of pulmonary arteries by circulating
egakaryocytes (99), CTEPH (100), POPH, and congestive
eart failure may all play a role. Splenectomy as a result of
rauma or as a treatment for hematologic disorders may
ncrease the risk of developing PH (101). CTEPH (102,103)
nd several cases of PAH (102,104) with medial hyper-
rophy, internal fibrosis, and plexiform lesions in the pul-
onary vasculature have been reported in association with
plenectomy.
.2. The second subgroup includes systemic disorders that
re associated with an increased risk of developing PH
105). Sarcoidosis is a common systemic granulomatous
isease of unknown origin. PH is an increasingly recognized
omplication of sarcoidosis (106), with a reported preva-
ence of 1% to 28% (107). PH is often attributed to the
estruction of the capillary bed by the fibrotic process
nd/or to the resultant chronic hypoxemia (108). However,
he severity of PH does not always correlate well with the
egree of parenchymal lung disease and blood gas abnormal-
ties, suggesting that other mechanisms may be contributing to
he development of PH (105). In this setting, such mecha-
isms could include extrinsic compression of large pulmonary
rteries by mediastinal and hilar adenopathy, and direct gran-
lomatous infiltration of the pulmonary vasculature, especially
he pulmonary veins, which sometimes mimic PVOD (109).
ore rarely, POPH secondary to hepatic involvement with
arcoidosis can be associated with the pathogenesis.
Pulmonary Langerhans cell histiocytosis is an uncommon
ause of infiltrative lung disease associated with destructive
hanges in the lung parenchyma. Severe PH is a common
eature in patients with end-stage pulmonary Langerhans
ells histiocytosis (110). In some patients, PH is probably
elated to chronic hypoxemia and/or abnormal pulmonary
echanics; in others, especially those patients with more
evere elevation of PAP, PH is unrelated to lung parenchy-
al injury. Histopathologic examination has shown severe
iffuse pulmonary vasculopathy involving predominantly
ntralobular pulmonary veins and, to a lesser extent, mus-
ular pulmonary arteries (111). These vascular changes
onsist of medial hypertrophy and intimal fibrosis.
Lymphangioleiomyomatosis is a rare multisystem disor-
er predominantly affecting women, characterized by cystic iung destruction, lymphatic abnormalities, and abdominal
umors. PH is relatively uncommon in patients with lym-
hangioleiomyomatosis (112,113). Chronic hypoxemia and
ulmonary capillary destruction caused by cystic lung lesions
robably represent the predominant causes of PH.
Neurofibromatosis type 1, also known as von Reckling-
ausen disease, is an autosomal dominant disease that can
e recognized by characteristic “café au lait” skin lesions and
y cutaneous fibromas. The disease is occasionally compli-
ated by systemic vasculopathy. Recently it was reported
hat the neurofibromatosis type 1 gene modulates protein
inase B, an important regulator of cell proliferation.
everal cases of PH have recently been reported in the
etting of von Recklinghausen disease (114–117). The
echanism of PH is unclear. Lung fibrosis and CTEPH are
hought to play a role. In rare cases, histologic examination
ound both arteries and veins narrowed by medial and/or
ntimal hypertrophy and fibrosis (117,118).
Lastly, some rare cases of PH have been observed in
ntineutrophil cytoplasmic antibodies-associated vasculitis;
he clinical presentation is similar to PAH, but histologic
ata are not available (119).
.3. The third subgroup comprises metabolic disorders. PH
as been reported in a few cases of type Ia glycogen storage
isease, a rare autosomal recessive disorder caused by a
eficiency of glucose-6-phosphatase (120–122). The mech-
nism of PH is uncertain but has been associated with
ortocaval shunts, atrial septal defects, or severe restrictive
ulmonary function defects. Thrombosis may also play a
ole in this setting. In 1 case, autopsy findings revealed the
resence of plexiform lesions (123).
Gaucher disease is a rare disorder characterized by a
eficiency of lysosomal B glucosidase, which results in an
ccumulation of glucocerebroside in reticuloendothelial
ells. Typical manifestations include hepatosplenomegaly
nd bone marrow infiltration. In a study of 134 patients
ith Gaucher disease who were systematically screened by
chocardiography, PH was not uncommon (124). In this
etting, several potential mechanisms for PH have been
uggested, including interstitial lung disease, chronic hypox-
mia, capillary plugging by Gaucher cells, and splenectomy
124,125). One case of histologic findings similar to idio-
athic PAH has been reported (126).
The association between thyroid diseases (hypothyroid-
sm and hyperthyroidism) and PH has been reported in a
umber of studies (127,128). In a recent prospective study
sing echocardiographic evaluation, more than 40% of
atients with thyroid diseases had PH (129). One instance
f PVOD confirmed by histology was observed in a patient
ith Hashimoto thyroiditis (130). Interestingly, a recent
rospective study of 63 consecutive adult patients with PAH
ound a 49% prevalence of autoimmune thyroid disease,
ncluding both hypothyroidism and hyperthyroidism, sug-
esting that these conditions may be linked by a common
mmunogenetic susceptibility (131).
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June 30, 2009:S43–54 Classification and Epidemiology.4. The last subgroup in category 5 includes a number of
iscellaneous conditions. In tumor obstruction, a tumor
rows into the central pulmonary arteries, with additional
ppositional thrombosis leading to a progressive obstruction
f proximal pulmonary arteries and PH. Such cases are due
rincipally to pulmonary artery sarcomas, occur rarely, and
re usually rapidly fatal (132,133). The differential diagnosis
ith CTEPH can be difficult. Computed tomography and
agnetic resonance imaging angiography are the most
seful diagnostic modalities for differentiation between
umor and thrombotic material (132,134,135).
Occlusion of the microvasculature by metastatic tumor
mboli represents another rare cause of rapidly progressive PH
136). The initial laboratory evaluation shows hypoxemia,
ften severe, with a clear lung field (137). Computed tomog-
aphy scanning does not show proximal thrombi but often
hows thickening of septa. In contrast, the V/Q lung scan is
enerally abnormal with multiple subsegmental perfusion de-
ects. Pulmonary microvascular cytology sampling through a
ulmonary artery catheter in the wedge position is an impor-
ant diagnostic tool (137). The majority of reported cases occur
n association with breast, lung, or gastric carcinomas.
Patients with mediastinal fibrosis may present with severe
H owing to compression of both pulmonary arteries and
eins (138,139). V/Q scan, computed tomography, and
ulmonary angiography are very useful for accurate diagno-
is, but findings can mimic proximal thrombotic obstruc-
ion. The predominant etiology is histoplasmosis (139),
lthough mediastinal fibrosis has been reported with other
ungal organisms, with tuberculosis (140), and in patients
ith sarcoidosis.
Lastly, PH has been reported in patients with end-stage
enal disease (ESRD) maintained on long-term hemodial-
sis. Based on echocardiographic studies, the prevalence of
H in this patient population is estimated at up to 40%
141). There are several potential explanations for the
evelopment of PH in patients with ESRD. Hormonal and
etabolic derangement associated with ESRD might lead
o pulmonary vascular constriction. The PAP may also be
ncreased by high cardiac output (resulting from the arte-
iovenous access itself and often concomitant anemia) as
ell as fluid overload. In addition, diastolic and systolic left
eart dysfunctions are frequent in this setting (142).
onclusions
n updating the classification of PH, we incorporated recent
ndings and sought to clarify areas of ambiguity. We believe
hat this version is both more comprehensive and more
omprehensible and hope that it will also be more useful to
linicians, pending further research into this diverse disease.
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